Orion Oyj/ FI0009014377 /
| 2024-04-18 5:24:55 PM | Chg. -0.02 | Volume | Bid5:25:00 PM | Ask5:25:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 32.32EUR | -0.06% | 92,405 Turnover: 1.33 mill. |
-Bid Size: - | -Ask Size: - | 3.45 bill.EUR | 5.02% | 20.95 |
GlobeNewswire
01-08
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ...
GlobeNewswire
01-05
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patient...
GlobeNewswire
2023-12-27
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
GlobeNewswire
2022-03-24
Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
GlobeNewswire
2022-02-18
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
GlobeNewswire
2022-02-17
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall surviva...
GlobeNewswire
2021-12-03
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets...
GlobeNewswire
2021-06-09
Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality...
GlobeNewswire
2019-12-09
Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
GlobeNewswire
2019-07-31
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant pro...
GlobeNewswire
2019-05-31
2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
